Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers

Addiction

Volumn 105, Issue 4, 2010, Pages 709-718

  Comer, Sandra D ^a   Sullivan, Maria A ^a   Vosburg, Suzanne K ^a   Manubay, Jeanne ^a   Amass, Leslie ^b   Cooper, Ziva D ^a   Saccone, Phillip ^a   Kleber, Herbert D ^a  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Abuse liability; Breakpoint; Buprenorphine naloxone; Drug liking; Heroin; Intravenous; Opioid dependence; Progressive ratio; Self administration

Indexed keywords

BUPRENORPHINE; NALOXONE; NARCOTIC AGENT; NARCOTIC ANTAGONIST;

ADDICTION; ADULT; ANALYSIS OF VARIANCE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; DRUG SELF ADMINISTRATION; ECONOMICS; FEMALE; HEROIN DEPENDENCE; HUMAN; MALE; MIDDLE AGED; PATIENT ATTITUDE; RANDOMIZED CONTROLLED TRIAL; SUBLINGUAL DRUG ADMINISTRATION; SUBSTANCE ABUSE; WITHDRAWAL SYNDROME;

ADMINISTRATION, SUBLINGUAL; ADULT; ANALYSIS OF VARIANCE; BEHAVIOR, ADDICTIVE; BUPRENORPHINE; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; HEROIN DEPENDENCE; HUMANS; MALE; MIDDLE AGED; NALOXONE; NARCOTIC ANTAGONISTS; NARCOTICS; PATIENT PREFERENCE; SELF ADMINISTRATION; SUBSTANCE ABUSE, INTRAVENOUS; SUBSTANCE WITHDRAWAL SYNDROME; YOUNG ADULT;

EID: 77949411784     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/j.1360-0443.2009.02843.x     Document Type: Article

References (40)

1. Carrieri M. P., Amass L., Lucas G. M., Vlahov D., Wodak A., Woody G. E. Buprenorphine use: the international experience. Clin Infect Dis 2006 43 : S197 215.
2. Teesson M., Mills K., Ross J., Darke S., Williamson A., Havard A. The impact of treatment on 3 years' outcome for heroin dependence: findings from the Australian Treatment Outcome Study (ATOS). Addiction 2008 103 : 80 8.
3. Mathers B. M., Degenhardt L., Phillips B., Wiessing L., Hickman M., Strathdee S. A. et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet 2008 372 : 1733 1745.
4. Gossop M., Marsden J., Stewart D., Treacy S. Reduced injection risk and sexual risk behaviours after drug misuse treatment: results from the National Treatment Outcome Research Study. AIDS Care 2002 14 : 77 93.
5. Gossop M., Marsden J., Stewart D., Kidd T. The National Treatment Outcome Research Study (NTORS): 4-5-year follow-up results. Addiction 2003 98 : 291 303.
6. Hubbard R. L., Craddock S. G., Anderson J. Overview of 5-year followup outcomes in the drug abuse treatment outcome studies (DATOS). J Subst Abuse Treat 2003 25 : 125 134.
7. Mattick R. P., Kimber J., Breen C., Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2008 2, CD002207.
8. Sullivan L. E., Metzger D. S., Fudala P. J., Fiellin D. A. Decreasing international HIV transmission: the role of expanding access to opioid agonist therapies for injection drug users. Addiction 2005 100 : 150 158.
9. Fatseas M., Auriacombe M. Why buprenorphine is so successful in treating opiate addiction in France. Curr Psychiatry Rep 2007 9 : 358 364.
10. Johnson R. E., Chutuape M. A., Strain E. C., Walsh S. L., Stitzer M. L., Bigelow G. E. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med 2000 343 : 1290 1297.
11. Alho H., Sinclair D., Vuori E., Holopainen A. Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users. Drug Alcohol Depend 2007 88 : 75 8.
12. Lee C. E. Tackling Subutex abuse in Singapore. Singapore Med J 2006 47 : 919 921.
13. Obadia Y., Perrin V., Feroni I., Vlahov D., Moatti J.-P. Injecting misuse of buprenorphine among French drug users. Addiction 2001 96 : 267 272.
14. Simojoki K., Vorma H., Alho H. A retrospective evaluation of patients switched from buprenorphine (Subutex) to the buprenorphine/naloxone combination (Suboxone). Subst Abuse Treat Prev Policy 2008 3 : 16.
15. Fudala P. J., Bridge T. P., Herbert S., Williford W. O., Chiang C. N., Jones K. et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med 2003 349 : 949 958.
16. Kamien J. B., Branstetter S. A., Amass L. Buprenorphine-naloxone (8/2 mg and 16/4 mg) versus methadone (45 mg and 90 mg) maintenance therapy: a randomised double-blind trial with opioid dependent patients. Heroin Addiction Related Clinical Problems 2010 in press.
17. Stoller K. B., Bigelow G. E., Walsh S. L., Strain E. C. Effects of buprenorphine/naloxone in opioid-dependent humans. Psychopharmacology (Berl) 2001 154 : 230 242.
18. Fudala P. J., Yu E., Macfadden W., Boardman C., Chiang C. N. Effects of buprenorphine and naloxone in morphine-stabilized opioid addicts. Drug Alcohol Depend 1998 50 : 1 8.
19. Preston K. L., Bigelow G. E., Liebson I. A. Buprenorphine and naloxone alone and in combination in opioid-dependent humans. Psychopharmacology (Berl) 1988 94 : 484 490.
20. Gal T. J. Naloxone reversal of buprenorphine-induced respiratory depression. Clin Pharmacol Ther 1989 45 : 66 71.
21. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington, DC : American Psychiatric Association 1994.
22. Comer S. D., Collins E. D., MacArthur R. B., Fischman M. W. Comparison of intravenous and intranasal heroin self-administration by morphine-maintained humans. Psychopharmacology (Berl) 1999 143 : 327 338.
23. McLeod D. R., Griffiths R. R., Bigelow G. E., Yingling J. An automated version of the Digit Symbol Substitution Test (DSST). Behav Res Meth Instrument 1982 14 : 463 466.
24. Miller T. P., Taylor J. L., Tinklenberg J. R. A comparison of assessment techniques measuring the effects of methylphenidate, secobarbital, diazepam and diphenhydramine in abstinent alcoholics. Neuropsychobiology 1988 19 : 90 6.
25. Roux P., Villes V., Blanche J., Bry D., Spire B., Feroni I. et al. Buprenorphine in primary care: risk factors for treatment injection and implications for clinical management. Drug Alcohol Depend 2008 97 : 105 113.
26. Gerra G., Borella F., Zaimovic A., Moi G., Bussandri M., Bubici C. et al. Buprenorphine versus methadone for opioid dependence: predictor variables for treatment outcome. Drug Alcohol Depend 2004 75 : 37 45.
27. Ling W., Wesson D. R. Clinical efficacy of buprenorphine: comparisons to methadone and placebo. Drug Alcohol Depend 2003 70 : S49 57.
28. Strain E. C., Stitzer M. L., Liebson I. A., Bigelow G. E. Dose-response effects of methadone in the treatment of opioid dependence. Ann Intern Med 1993 119 : 23 7.
29. Strain E. C., Stitzer M. L., Liebson I. A., Bigelow G. E. Methadone dose and treatment outcome. Drug Alcohol Depend 1993 33 : 105 117.
30. Eissenberg T., Johnson R. E., Bigelow G. E., Walsh S. L., Liebson I. A., Strain E. C. et al. Controlled opioid withdrawal evaluation during 72 h dose omission in buprenorphine-maintained patients. Drug Alcohol Depend 1997 45 : 81 91.
31. Comer S. D., Sullivan M. A., Walker E. A. Comparison of intravenous buprenorphine and methadone self-administration by recently detoxified heroin-dependent individuals. J Pharmacol Exp Ther 2005 315 : 1320 1330.
32. Comer S. D., Ashworth J. B., Foltin R. W., Johanson C. E., Zacny J. P., Walsh S. L. The role of human drug self-administration procedures in the development of medications. Drug Alcohol Depend 2008 96 : 1 15.
33. JBS International, Inc. Diversion and Abuse of Buprenorphine: A Brief Assessment of Emerging Indicators: Final Report. Silver Spring, MD : Substance Abuse and Mental Health Services Administration Center for Substance Abuse Treatment 2006. Available at: http://buprenorphine.samhsa.gov/Buprenorphine- FinalReport-12.6.06.pdf (accessed 14 November 2009).
34. Fiellin D. A., Moore B. A., Sullivan L. E., Becker W. C., Pantalon M. V., Chawarski M. C. et al. Long-term treatment with buprenorphine/naloxone in primary care: results at 2-5 years. Am J Addict 2008 17 : 116 120.
35. Fiellin D. A., Pantalon M. V., Chawarski M. C., Moore B. A., Sullivan L. E., O'Connor P. G. et al. Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence. N Engl J Med 2006 355 : 365 374.
36. Lintzeris N., Ritter A., Panjari M., Clark N., Kutin J., Bammer G. Implementing buprenorphine treatment in community settings in Australia: experiences from the Buprenorphine Implementation Trial. Am J Addict 2004 13 : S29 41.
37. Jenkinson R. A., Clark N. C., Fry C. L., Dobbin M. Buprenorphine diversion and injection in Melbourne, Australia: an emerging issue? Addiction 2005 100 : 197 205.
38. Aitken C. K., Higgs P. G., Hellard M. E. Buprenorphine injection in Melbourne, Australia - an update. Drug Alcohol Rev 2008 27 : 197 199.
39. Bell J., Shanahan M., Mutch C., Rea F., Ryan A., Batey R. et al. A randomized trial of effectiveness and cost-effectiveness of observed versus unobserved administration of buprenorphine-naloxone for heroin dependence. Addiction 2007 102 : 1899 1907.
40. Bell J. R., Ryan A., Mutch C., Batey R., Rea F. Optimising the benefits of unobserved dose administration for stable opioid maintenance patients: follow-up of a randomised trial. Drug Alcohol Depend 2008 96 : 183 186.